S116836
Modify Date: 2025-09-20 20:28:15
S116836 structure
|
Common Name | S116836 | ||
|---|---|---|---|---|
| CAS Number | 1257628-57-1 | Molecular Weight | 502.49 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C27H21F3N6O | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of S116836S116836, a potent, orally active BCR-ABL tyrosine kinase inhibitor (TKI), blocks both wild-type as well as T315I Bcr-Abl. S116836 potently inhibits the phosphorylation of BCR-ABL and induces apoptosis. S116836 inhibits growth of WT and T315I mutant BCR-ABL tumors and does not cause significant cardiotoxicity. S116836 also inhibits SRC, LYN, HCK, LCK and BLK, and receptor tyrosine kinases such as FLT3, TIE2, KIT, PDGFR-β. Antitumor activies[1][2][3]. |
| Name | S116836 |
|---|
| Description | S116836, a potent, orally active BCR-ABL tyrosine kinase inhibitor (TKI), blocks both wild-type as well as T315I Bcr-Abl. S116836 potently inhibits the phosphorylation of BCR-ABL and induces apoptosis. S116836 inhibits growth of WT and T315I mutant BCR-ABL tumors and does not cause significant cardiotoxicity. S116836 also inhibits SRC, LYN, HCK, LCK and BLK, and receptor tyrosine kinases such as FLT3, TIE2, KIT, PDGFR-β. Antitumor activies[1][2][3]. |
|---|---|
| Related Catalog | |
| Target |
Bcr-AblWT Bcr-AblT315I |
| In Vitro | S116836 (0.01-1 μM; 24 hours) significantly reduces the cellular proliferation of BaF3/WT and BaF3/T315I cells (IC50 values of 0.05 μM and 0.20 μM, respectively)[1]. S116836 (0.01-1 μM； 24 hours) significantly downregulates the expression level of p-BCR-ABL in BaF3/WT cells[1]. S116836 (0.01-1 μM; 24 hours) significantly downregulates the expression level of p-BCR-ABL in Imatinib-resistant BaF3/T315I cells[1]. S116836 (0.01-1 μM; 24 hours) significantly downregulates the expression level of p-Crkl and p-STAT5 (downstream signaling proteins of BCR-ABL) in both BaF3/WT and BaF3/T315I cells[1]. S116836 (0.1, 0.3, and 0.5 μM; 24 hours) arrests the BaF3/WT and BaF3/T315I cells in G0/G1 phase of the cell cycle[1]. S116836 (0.3 and 0.5 μM; 24 hours) increases ROS production and decreases GSH levels in BaF3/WT and BaF3/T315I cells[1]. S116836 (0.1, 0.3, and 0.5 μM; 24 hours) induces apoptosis in BaF3/WT and BaF3/T315I cells[1]. SAHA and S116836 synergistically induce apoptosis in imatinib-resistant chronic myelogenous leukemia cells[2]. S116836 potently inhibits PDGFRα and its downstream signaling molecules such as STAT3, AKT, and Erk1/2. S116836 effectively inhibits the growth of the WT and T674I FIP1L1-PDGFRα-expressing neoplastic cells. S116836 induces intrinsic pathway of apoptosis as well as the death receptor pathway, coincided with up-regulation of the proapoptotic BH3-only protein Bim-EL through the Erk1/2 pathway[3]. |
| In Vivo | S116836 (100 or 200 mg/kg; i.p.; q3d×6, athymic NCR nude mice) decreases the volume and weight of xenograft tumors expressing WT and T315I mutant BCR-ABL[1]. S116836 (200mg/kg/d, oral gavage for 14 days) inhibits the growth of xenografted T674I-FIP1L1-PDGFRα cells in nude mice[3]. |
| References |
| Molecular Formula | C27H21F3N6O |
|---|---|
| Molecular Weight | 502.49 |
| InChIKey | DHNAWOULRSDMRU-UHFFFAOYSA-N |
| SMILES | Cc1ccc(C(=O)Nc2cc(-n3ccnc3)cc(C(F)(F)F)c2)cc1C#Cc1cnc(NC2CC2)nc1 |